Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | AKT1 | P31749 | 2/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | CDC25A | P30304 | 1/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.62 |
| ▸ | PRKCB | P05771 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | PRKCH | P24723 | 1/20 | 0.62 |
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853628 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL30008220 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10938318 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10937575 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934199 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016704 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL18952927 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL10415339 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Oleylphosphocholine SCHEMBL3332097 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016878 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828972-B2 | Formulations containing alkylphosphocholines using novel negative charge carriers | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-1827379-B8 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MAX PLANCK GESELLSCHAFT (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-1827379-B1 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MAX PLANCK GESELLSCHAFT (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1827379-A2 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006042751-A2 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2006-04-27 | — | — | WO | disclosed |
| EP-0507337-B1 | Novel erucyl, brassidyl and nervonyl derivatives | MAX PLANCK GESELLSCHAFT (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5436234-A | Treatment of protozoal and fungal diseases, autoimmune diseases and bone marrow damage | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG (DE) | 1995-07-25 | — | — | US | disclosed |
| EP-0507337-A2 | Novel erucyl, brassidyl and nervonyl derivatives | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | PHOSPHO1, SGMS2, LPCAT1 | LMNA 562/4885AKT1 1248/4885ESR1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.